Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Heart Valves in Europe: The Mix Will Change

This article was originally published in Start Up

Executive Summary

According to "European Markets for Heart Valve Repair and Replacement Products," Medtech Insight's recent report, in the coming years growth in the heart valve industry will be somewhat flat in Europe-with a compound annual growth rate in the overall number of procedures of 1.6% between now and 2013. However, that number reflects a drop in the number of mechanical valves used, and a rise in tissue valves, which are enjoying increased uptake with each generation of technological improvements.

You may also be interested in...



Biologic Valves Are As Good As Mechanical Valves In Younger Patients, Study Shows

Bioprosthetic replacement heart valves may be a reasonable alternative to mechanical valves in patients aged 50 to 69 years, according to a retrospective cohort analysis of 4,253 patients.

Abbott Moves into Heart Valves with Evalve Deal

The hottest major interventional cardiology company, Abbott, moves into the hottest interventional clinical space, catheter-based heart valve therapy, with the acquisition of Evalve, providing Abbott with a platform to build a structural heart disease device business.

Evalve, Mitralign Deals: Heart Valves Draw New Device Investors

Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device market with venture investors. This popularity has resulted in some VCs concluding that the space has become saturated. While the market may be getting tougher to enter for newcomers, the successful financing rounds recently closed by Evalve and Mitralign show that investors--including new device investors--remain bullish on companies that can demonstrate an effective percutaneous alternative to existing surgical procedures.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel